Nicox SA
Company Profile
Business description
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
Contact
Rue Evariste Galois
Emerald Square, Batiment C
Sundesk Sophia Antipolis
Biot06410
FRAT: +33 497245300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
A look into newly listed Glencore’s valuation
stocks
Meta is up 9% this year. Is it still a buy ahead of earnings?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,934.50 | 9.70 | -0.11% |
| CAC 40 | 7,838.49 | 29.56 | -0.38% |
| DAX 40 | 25,304.42 | 15.35 | -0.06% |
| Dow JONES (US) | 52,495.88 | 529.85 | 1.02% |
| FTSE 100 | 10,733.00 | 31.69 | -0.29% |
| HKSE | 23,830.50 | 37.24 | -0.16% |
| NASDAQ | 26,424.82 | 6.07 | -0.02% |
| Nikkei 225 | 64,823.55 | 748.13 | 1.17% |
| NZX 50 Index | 13,735.54 | 103.85 | 0.76% |
| S&P 500 | 7,712.57 | 21.84 | 0.28% |
| S&P/ASX 200 | 8,808.20 | 8.70 | -0.10% |
| SSE Composite Index | 3,722.41 | 12.96 | -0.35% |